primary sedative for patients requiring prolonged ventilation and continuous propofol or midazolam for patients requiring short-term (48 -72 hrs) ventilation (5) . Although these and other sedatives have been compared in past studies, few have been assessed rigorously with high-quality, randomized clinical trials that included outcomes such as duration of ventilation and length of hospital stay (6) . To our knowledge, only two randomized clinical trials evaluating sedation regimens have been published that also incorporated daily trials of awakening from sedation, an intervention now widely utilized (7, 8) . Neither of these studies, one comparing midazolam with propofol and the other comparing propofol with intermittent lorazepam, reported a survival advantage to any specific sedative regimen (7, 8) .
Given the lack of mortality differences among these three sedatives, factors such as costs and clinical outcomes, such as frequency of adverse events, duration of mechanical ventilation, and length of stay, could be useful in differentiating the value of these products that are part of the $180 billion spent annually on critical care in the United States (7, 9 -11) . Although propofol may facilitate weaning when compared with lorazepam, it is significantly more costly than lorazepam and is associated with significant hemodynamic and metabolic side effects (12, 13) . Because of these concerns, many practitioners use midazolam because it is perceived to have a considerably shorter half-life than lorazepam and is less expensive than propofol. However, accumulation of midazolam and its active metabolites is likely to occur in critically ill patients, potentially causing prolonged sedation (14) .
Because of the strong association between ICU length of stay and costs, identification of safe and effective sedative options that can also reduce resource utilization during a time of changing population demographics is important for policy makers and clinicians alike (15, 16) . However, we know of no formal economic analyses comparing sedatives in the setting of contemporary critical care practice. Therefore, we performed costeffectiveness analysis comparing continuous propofol and intermittent lorazepam for the sedation of critically ill adults, with secondary analyses including midazolam.
METHODS

Study Design
We used a decision analysis model to compare the value of continuous propofol and intermittent lorazepam in our base-case analysis (Fig. 1) . In secondary analyses, we compared continuous midazolam with both propofol and lorazepam because they are the three most commonly used sedatives in an ICU setting (17) . We did not include midazolam as part of the primary analysis because of the lack of data on its direct comparison with lorazepam in the setting of daily awakening from sedation. We assumed that if patients tolerated the sedative, they then survived or died based on model inputs. Patients who experienced a sedative-associated adverse event crossed over to the comparator sedative, accruing costs and effects to the initial treatment while achieving the intended therapeutic effect with the second sedative.
We followed recommendations for the conduct of cost-effectiveness analyses whenever possible, although with some notable departures due to the unique nature of the patient group and interventions compared (18) . First, instead of the recommended societal perspective, we conducted the analysis from the perspective of the hospital because prospective payment reimbursement structures in place between hospitals and payors create incentives for providers to minimize costs. Also, because there is no known longterm survival advantage to any particular sedation protocol, we limited the time horizon to 28 days from the initiation of mechanical ventilation. All costs were adjusted to 2007 U.S. dollars using the Medical Care component of the U.S. Consumer Price Index (19) . Because of the short time horizon, costs were not discounted.
Our primary data sources included original data from randomized controlled trials published by Carson et al. (7), comparing propofol with intermittent lorazepam, and Kress et al. (8) , who randomized patients to propofol vs. midazolam and to daily awakening trials vs. no awakening. Patients were enrolled in these studies if they had an anticipated requirement for mechanical ventilation of Ͼ48 hrs and required significant amounts of sedatives either in the form of continuous infusions or more than minimal doses of lorazepam. We also included data from what we thought were relevant, highquality studies (Table 1) .
Patient Population and Process of Care Characteristics
Base-Case Patient. We modeled the basecase patient on the cohort composition reported in the Carson et al. (7) study in which patients were 55 yrs old and managed in a medical ICU. We also assumed patients would receive screening daily for the appropriateness of spontaneous breathing trials in anticipation of ventilator liberation and that daily awakening trials were performed in which sedatives were stopped each morning until patients could follow simple commands.
Sedative and Analgesic Dosing. Estimates of sedative and analgesic dosing were based on original data from the Carson et al. (7) and Kress et al. (8) studies (Table 1) . Sedative doses were targeted to achieve a Ramsay sedation score of 3 (responds to command only) or 4 (asleep but with a brisk response to a light glabellar tap or loud sound) in the Kress study and 2 (cooperative, oriented, and tranquil) or 3 (responds to command only) in the Carson study (20) . The protocols for dosing continu- Figure 1 . Decision model. This is a simplified version of the decision model used in analyses. In this model, patients ventilated for Ն48 hrs could either receive propofol or lorazepam for sedation. Progression through the decision tree over the course of the succeeding 28 days examined was determined by probabilities defined in Table 1 . ICU, intensive care unit. ICU, intensive care unit; CT, computerized tomography. Propofol and midazolam assumed to have clinical equivalence with the exceptions of side effect profile (assumed to mirror lorazepam) and costs.
a Number in parentheses represents SE. For point estimates presented as percentages, the sample size was 132 (64 in lorazepam group and 68 in propofol group).
b Costs were added for propofol recipients who developed hypertriglyceridemia (two extra serum triglyceride levels) and propofol-associated pancreatitis (daily lipase level while in the ICU, one abdomen and pelvis computerized tomography with and without contrast, and two extra ICU days with ventilation). Lorazepam recipients who developed an associated metabolic acidosis were assumed to require one extra ventilator day.
c Hypertriglyceridemia was defined as serum triglyceride level of Ͼ500 mg/dL, and pancreatitis was defined as either serum amylase of Ն125 IU/L or lipase of Ն60 IU/L.
d Based on costs from Duke University Medical Center. e We assumed ICU day 1 required Ͼ104 mins of critical care time (current procedural terminology [CPT] 99291 ϩ 99292); other ICU days with intubation required 30 -74 minutes of critical care time (CPT 99291) and both postextubation ICU care (CPT 99233) and hospital ward care (CPT 99232) (27) . ous propofol, continuous midazolam, intermittent lorazepam, and morphine have been described elsewhere (7, 8) .
Adverse Events. We recognized that the sedative initially prescribed might either provide inadequate sedation or lead to untoward adverse effects, necessitating crossover to the comparator drug. For the base-case analysis, we assumed that patients who did not tolerate propofol crossed over to lorazepam and vice versa. In secondary analyses in which midazolam was included, we assumed that propofolintolerant patients received midazolam and vice versa. Expenses related to the adverse effects of sedatives are shown in Table 1 .
Overall base-case crossover rates (6% for propofol and 8% for lorazepam) were based on Carson et al (7) . We assumed that the failure rate for midazolam would approximate that of lorazepam (8%). Adverse effects of propofol (inadequate sedation, hypertriglyceridemia, pancreatitis, and hemodynamic instability), lorazepam (inadequate sedation and metabolic acidosis related to the drug's propylene glycol carrier), and midazolam (inadequate sedation) were included in the model and their input values in sensitivity analyses defined by ranges reported in the relevant literature (12, 13, 21, 22) .
Equivalence of Comparisons Between Midazolam and Propofol Recipients. Our model assumed that clinical outcomes (although not drug costs) of those receiving midazolam were equivalent to propofol recipients based on the study by Kress et al (8) . This study reported no significant differences in clinical characteristics or outcomes, including length of stay and mortality, between propofol and midazolam recipients who received daily awakenings from sedation. We independently verified this equivalency through our own statistical analyses of the original Kress et al. (8) data set (not shown).
Clinical Effects
We expressed our results in terms of costs and both mechanical ventilator-free days and mechanical ventilator-free survival. Mechanical ventilator-free days were defined as the total number of days free from mechanical ventilation within the first 28 days from the time of intubation. Mechanical ventilator-free survival was defined as the total number of days free from mechanical ventilation within the first 28 days from the time of intubation for hospital survivors. The validity and utility of using ventilator-free days as an outcome in critical care research has been described elsewhere (23).
Hospital Outcomes
Because there is no proven survival difference between those receiving propofol, lorazepam, or midazolam, we assumed that ICU and hospital mortality were equivalent in all groups. Further, we assumed that the average duration of hospitalization was equal for all groups based on the work of Carson et al (7) . The primary differences among groups were related to length of ICU stay and duration of mechanical ventilation, outcomes that differed based on ICU survivorship status (7, 8) .
Costs
Only direct costs were incorporated in the model (Table 1) . Although costs were estimated using a variety of sources relevant to different stakeholders in this issue, we incorporated published costs from national database sources when possible to maximize the ability to generalize our results. We held unit costs static in the base-case probabilistic model, although varied important cost variables in one-way sensitivity analyses.
Pharmacy. Drug prices were representative of 2007 national wholesale acquisition costs to provide better estimates of the actual cost borne by a hospital system compared with the use of average wholesale prices (24) . We have included in our one-way sensitivity analyses wide variance in drug costs to account for the potential diversity in actual costs encountered by different providers. In general, the cost range examined in sensitivity analyses represents Ϯ50% of the wholesale acquisition cost, with the exception that propofol's upper bound corresponded to the wholesale acquisition cost for the branded product Diprivan.
Hospitalization. Daily ICU costs were based on the medical subset of patients drawn from a larger national sample of 51,000 critically ill ventilated patients (25) . A lower range for ICU cost in sensitivity analyses was the daily Medicare reimbursement rate for diagnosis-related group 565 (mechanical ventilation for Ն96 hrs). This was calculated by dividing the average diagnosis-related group payment ($28,837) by its corresponding mean length of stay (15.8 days). The upper range was established by inflating the basecase daily ICU cost by 50%. Daily hospital ward costs were based on Medical Provider Analysis and Review (MEDPAR) analyses of general ICU patients utilizing the Russell equation, and cost ranges used in sensitivity analyses were calculated by adding and subtracting 50% of the base-case cost (26) . We included professional costs for the primary treating physician based on current procedural terminology codes and Medicare fee schedules, varying these costs Ϯ50% in sensitivity analyses (27) .
Probabilistic and Sensitivity Analyses
Because of the uncertainty in some of our base-case estimates, we elected to present our main results based on probabilistic analyses generated using Monte Carlo simulation rather than deterministic analyses that would have generated only point estimates. Specifically, for probabilistic analyses, we first specified distributions for all input variables. We used gamma distributions to model continuous variables and beta distributions to model dichotomous variables (Table 2 ). The sample size (n ϭ 132) used to calculate standard errors for probability distributions was based on the number of patients enrolled in the Carson et al. (7) study. Next, average values of 1,000 separate simulations were reported along with cost-effectiveness scatterplots. We also performed one-way and two-way sensitivity analyses to understand how varying data inputs across prespecified ranges (not distributions) could affect point estimates of costs and effectiveness ( Table 2 ). We used Excel (Microsoft, Redmond, WA) to develop the cost-effectiveness analysis and Stata 9 (Stata, College Station, TX) for statistical analyses. These analyses were judged exempt from formal institutional review board review by 45 CFR 46.101(b) because they utilized previously collected, completely de-identified data.
RESULTS
In our base-case scenario, we found that propofol clearly dominated lorazepam based on its comparatively lower overall costs ($45,631 vs. $52,009) and greater effects, as quantified by a gain of more than three mechanical ventilatorfree days (Table 2 ). In fact, propofol was less costly or more efficacious in 94% and 90% of 1,000 simulations performed, respectively. In 91% of simulations, propofol was both less costly and more efficacious.
Our secondary probabilistic analyses demonstrated that allowing propofol crossover to midazolam instead of lorazepam in the setting of associated adverse events produced results similar to the base case (Table 2 ). In addition, midazolam's dominance of intermittent lorazepam in direct comparison was consistent with the base-case analysis comparing propofol with lorazepam. We found no meaningful differences between propofol and midazolam on costs or effectiveness, however. The superimposed clustering of 1,000 comparative simulations shown in Figures 2 and 3 demonstrates that the true difference in value between the two is unlikely to be clinically important.
Although we found little evidence to favor propofol over midazolam, we were interested in exploring how robust our analyses were when comparing the two sedatives. Table 3 shows the results of varying average duration of ventilation by group because this variable seemed to have the greatest effect on sedative value in our model. Assuming clinical, not cost, equivalence in these two sedatives, there is a minor cost advantage per case seen with midazolam ($319) relative to propofol. However, varying the difference in average ventilation duration by as little as 1 day had important effects on costs and ventilator-free days. For example, if propofol use is actually associated with one fewer day of ventilation relative to midazolam, overall comparative costs are $6,286 less, with an average gain of 0.354 ventilator-free days. The opposite effect occurred when we assumed that midazolam was associated with a 1-day reduction in ventilator days compared with propofol.
Across the range of one-way sensitivity analyses, propofol use was associated not only with gains in the number of ventilator-free days but also with lower costs in comparison with lorazepam, as shown in the tornado diagram (Fig. 4) . The only realistic scenario in which lorazepam was more effective than propofol was when the propofol-to-lorazepam ratio of ventilator days exceeded 1.5. For example, assuming propofol use resulted in an average ventilation duration of 6 days, lorazepam use would theoretically result in greater numbers of ventilator-free days only when the average duration of ventilation for this group was Ͻ4 days (that is, 6 days/1.5) owing to the comparatively longer duration of ventilation and ICU care among lorazepam survivors of ventilation. Drug and physician costs had a minor impact on overall costs and effects in these sensitivity analyses.
DISCUSSION
Clinicians' practice of prescribing and monitoring the use of sedatives among the hundreds of thousands of patients receiving mechanical ventilation in ICUs annually has profound implications. Sedation use is intimately associated not only with patient comfort but with the duration of mechanical ventilation, incidence of delirium, and overall resource utilization (28, 29) . Because of the comparatively high cost of each ventilator day and the observation that many ICU patients may generate a net financial loss primarily related to ICU length of stay, healthcare providers should search preferentially for interventions and therapies designed to decrease days of ventilation (26). Given the advancing age of the U.S. population and expected increase in critical care utilization in the coming decades, planning for future needs in a climate of potential economic restraint and resource limitation is crucial in the resource-intensive ICU setting (30) . Therefore, the results of our economic analysis have contemporary importance for physicians, pharmacists, administrators, and policy makers and add to the relatively small body of critical care cost-effectiveness research (15, 31) .
We believe that there is a common perception that propofol use is inherently expensive in comparison with lorazepam and that favoring the latter in routine clinical practice may conserve resources (32) . However, our analyses show that propofol has superior value when compared with lorazepam and may have equivalent value to midazolam when daily interruption of sedation occurs. We found that in nearly all scenarios and simulations, the use of propofol for sedation is associated with lower overall costs and greater ventilator-free days when compared with lorazepam. In fact, despite lorazepam's considerably lower pharmacy unit cost, its use results in additional days of mechanical ventilation. This in turn increases the risk of ventilatorassociated pneumonia and other costly and morbid time-dependent hazards of critical care (33) . We believe that this and other studies suggest that using lorazepam for the sedation of mechanically ventilated patients who require more than minimal amounts of sedation conveys few advantages (29) .
It is difficult to compare our work with the existing medical literature examining sedatives from an economic perspective because these past studies were undertaken before clinical practice advanced to include daily awakenings from sedation and spontaneous breathing trials. It is likely that without daily interruption of continuous infusions, the difference in effectiveness between propofol or midazolam and lorazepam would be less. Additional limitations of past work include incorporation of medication costs instead of overall hospitalization costs, data collection within different countries during times when comparative exchange rates are difficult to now appreciate, consideration of only short-term sedation, lack of use of sensitivity analysis to examine the effect of data input uncertainty, and inclusion of propofol costs based on its more expensive branded formulation (32, 34 -37) .
Because of the ubiquity of sedative use in the ICU setting, we believe that our results underscore the importance of determining whether clinically important differences exist among commonly used sedatives with respect to mechanical ventilation-free days and length of stay. For example, assuming equivalence in ventilator-free days and length of stay, a hospital treating 1,000 ventilated patients annually could theoretically save more than $300,000 by using midazolam instead of propofol. However, if midazolam use was actually associated with even one extra ICU day, the balance would swing in the opposite direction, with a comparative annual opportunity loss of more than $2.5 mil- lion. Even an extra hospital ward day would represent more than $385,000 in additional costs. The tens of thousands of ventilated patients managed daily magnify the potential implications of these unclear outcomes differences. Interestingly, our analyses suggest that even newer, more expensive sedatives such as dexmedetomidine (average cost, $300 -500 per day) are likely to have favorable value in comparison with other sedatives if their primary or adjunctive use is associated with a comparative reduction in either ICU or hospital length of stay by as little as 1 day (38) .
Our study has limitations that are important to highlight. First, we have utilized data from different sources. Although we gathered these data from what we thought were the highest quality studies, there may be bias inherent in this practice. Another factor worth considering is our use of data from two different trials to estimate values for key variables in the model for propofol and midazolam. Although we performed our own analyses of these studies' primary data to establish that no significant differences existed between these groups' clinical outcomes (not shown), there could nonetheless be an underappreciated difference. Still, when we applied various ranges of input variables and outlined assumptions that seemed reasonable given the absence of a larger comparative randomized trial, our results were upheld. Third, our metric of cost per mechanical ventilator-free day is relatively novel in the cost-effectiveness literature. However, its use as an outcome measure in critical care is increasingly accepted and practical considering its salutary effect on sample sizes in clinical trials (23) . Also, because the effect of switching from one sedative to a less expensive alternative as the summative days of ventilation accrue is unknown, we were unable to include this strategy in our model. Also, we were unable to incorporate the independent effect of sedative-associated delirium because of source data limitations (29) . Finally, because the effect of different sedative regimens on long-term outcomes and costs is unknown, our model was focused on acute care outcomes. Although we believe our model is helpful for clinicians caring for typical critically ill patients, it is intended to augment and not replace clinical judgment in decision making.
CONCLUSION
In conclusion, the use of continuous propofol for sedation of patients receiving mechanical ventilation results in significantly lower overall costs and a greater number of ventilator-free days in comparison with intermittent lorazepam. The routine use of lorazepam as the primary sedative choice should be discouraged based on its comparatively poor value in this particular critical care setting. Contemporary, adequately powered comparative studies of common sedatives, including propofol and midazolam, are also needed to determine whether either has a comparative economic advantage.
